Quo vadis, neutrophil?

Rodrigo J Gonzalez, Ulrich H von Andrian

Abstract readComment

In one paragraph

Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

1.0field-weighted citation impact, top 29% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

Associations of Inflammatory Markers and Coronary Heart Disease in Different Gender Groups in Cohort NHANES 2003-2018.Cardiology research and practice · 2026
Article
Quo Vadis Temporomandibular Disorders? By 2050, the Global Prevalence of TMD May Approach 44.Journal of clinical medicine · 2025
Article
A Small Molecule Chemiluminophore with near 600 nm Emission for In Vivo Imaging of Myeloperoxidase and Inflammatory Diseases.Chemical & biomedical imaging · 2024
Article
The relationship between a series of inflammatory markers on the risk of heart failure in different gender groups: Analysis from NHANES 2015-2018.PloS one · 2024
Article
Store-operated calcium entry enhances the polarization and chemotaxis of neutrophils in the peripheral venous blood of patients with bronchial asthma by upregulating ERM protein.Journal of thoracic disease · 2023
Article
GPR35 acts a dual role and therapeutic target in inflammation.Frontiers in immunology · 2023
Review

4 · The record

Corrections and comments

Comment on
GPR35 promotes neutrophil recruitment in response to serotonin metabolite 5-HIAA.2022

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Rodrigo J GonzalezDepartment of Immunology, Harvard Medical School, Boston, MA, USA; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.

Ulrich H von AndrianDepartment of Immunology, Harvard Medical School, Boston, MA, USA; The Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA. Electronic address: uva@hms.harvard.edu.

Ragon Institute of MGH, MIT and Harvard · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neutrophil recruitment from blood into tissues is a hallmark of inflammation and anti-microbial host defense. In this issue, De Giovanni et al. describe an unanticipated role for a serotonin metabolite, 5-HIAA, which is produced by activated platelets and mast cells and engages the orphan receptor, GPR35, to recruit neutrophils to inflamed tissues.

Indexed as

Blood PlateletsNeutrophilsHumansInflammationMast CellsNeutrophil Infiltration

Identifiers

PMID35245478

DOI10.1016/j.cell.2022.02.009

OpenAlexW4214941076

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.